Enter inventor name

Gerald McMahon

This inventor holds 65 USPTO granted patents, primarily in Protein Kinase Inhibitors (CPC class C07D). Top assignees: Sugen Incorporated, Asta Medica, Aktiengesellschaft, Zentaris Ag. Active years: 1997-2007.

USPTO Granted Patents = 65

% Patents Active = 78.5

Average Co-Inventor Count = 3.2

ph-index = 26

Forward Citations = 2,042(Granted Patents)

Forward Citations (Not Self Cited) = 1,985(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Kenwood, CA (US) (1997 - 2007)
San Francisco, CA (US) (1998 - 2007)

Company Filing History:

Asta Medica, Aktiengesellschaft

5. 1 out of 834,307

Other

patents

Years Active: 1997-2007

Loading Chart...

Areas of Expertise:

Protein Kinase Inhibitors

Indolinone Compounds

Quinoxaline Derivatives

Tyrosine Kinase

Serine/Threonine Modulation

Combinatorial Libraries

Bicyclic Compounds

Phosphatase Inhibitors

Bioavailability

Pharmaceutical Compositions

Azaindole Compounds

Heteroaryl Derivatives

65 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7211600 - [object Object] (2007-05-01),

2. 7202265 - Indolinone combinatorial libraries and related products and methods for the treatment of disease (2007-04-10),

3. 7189721 - Bicyclic protein kinase inhibitors (2007-03-13),

4. 7119090 - Pyrrole substituted 2-indolinone protein kinase inhibitors (2006-10-10),

5. 6987113 - Tyrosine kinase inhibitors (2006-01-17),

6. 6911446 - Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds (2005-06-28),

7. 6908930 - 4-substituted 7-AZA-indolin-2-ones and their use as protein kinase inhibitors (2005-06-21),

8. 6906093 - Indolinone combinatorial libraries and related products and methods for the treatment of disease (2005-06-14),

9. 6855723 - Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds (2005-02-15),

10. 6849641 - Azaindole tyrosine kinase inhibitors (2005-02-01),

11. 6727252 - Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds (2004-04-27),

12. 6696463 - 3-heteroarylidenyl-2-azaindolinones active as protein tyrosine kinase inhibitors (2004-02-24),

13. 6696448 - 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors (2004-02-24),

14. 6689806 - Indolinone compounds as kinase inhibitors (2004-02-10),

15. 6683082 - Bicyclic protein kinase inhibitors (2004-01-27),

Title: The Innovative Journey of Gerald McMahon

Introduction

Gerald McMahon, based in Kenwood, California, is a prominent inventor known for his significant contributions to the field of biotechnology. With an impressive portfolio of 65 patents, McMahon has made substantial advancements in therapeutic compounds aimed at addressing critical medical conditions.

Latest Patents

Among his latest inventions, McMahon focuses on compounds that inhibit the activity of receptor tyrosine kinases, specifically targeting conditions such as cell proliferative disorders and cancers linked to c-kit kinase activity. His work includes the development of indolinone combinatorial libraries, which are organic molecules designed to modulate and inhibit protein kinase signal transduction. These compounds have implications for treating various diseases, including cancer, atherosclerosis, arthritis, restenosis, and diabetes. His innovative indolinone compounds, particularly those modified with specific chemical substituents, have shown promise in effectively activating and inhibiting protein kinases.

Career Highlights

Throughout his career, Gerald McMahon has worked with notable companies in the biotechnology sector, including Sugen Incorporated and Asta Medica, Aktiengesellschaft. His tenure at these firms has not only advanced his research but has also established him as a notable figure in pharmaceutical innovation.

Collaborations

McMahon has collaborated with prominent colleagues in the field, including Peng Cho Tang and Li Hsiang Sun. Together, they have contributed to the development of breakthrough research that pushes the boundaries of current medical treatments.

Conclusion

Gerald McMahon's inventive spirit and dedication to solving complex health issues through innovation continue to make a significant impact. With a strong patent portfolio and collaborative efforts, he remains a key player in advancing therapeutic solutions that address critical health challenges.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to [email protected]